EUVIMEDEUVIMED entdecken
Crossref

Structure-based drug repurposing and in vitro evaluation of VAV2-associated candidates for suppression of macrophage foam-cell formation in atherosclerosis

Prerna Bansal, Kamna Srivastava iD

Molecular Diversity · 19.09.2026 · 30 (6) · 11153-11176

DOI: 10.1007/s11030-026-11713-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Diversity, online erschienen am 19.09.2026. Verfasst von Prerna Bansal und 1 weiteren Autor:innen. Beteiligte Einrichtung: Dr. B.R. Ambedkar Center for Biomedical Research, University of Delhi, Delhi, 110007, India. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-vav, Foam Cells, Atherosclerosis, Drug Repositioning. Die Arbeit nennt 63 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiovascular disease remains a leading cause of mortality worldwide, and macrophage-derived foam-cell formation represents an important event in atherosclerosis. VAV2, a Rho-family guanine nucleotide-exchange factor, participates in signalling pathways associated with oxidized low-density lipoprotein uptake and macrophage lipid accumulation. In this study, a structure-based drug-repurposing workflow was used to identify clinically relevant compounds with predicted affinity for a full-length VAV2 structural model. Virtual screening, molecular docking, ADMET prediction, three independent 200-ns molecular-dynamics simulations, principal-component analysis, and MM-PBSA calculations prioritized talazoparib, tivozanib, and isradipine for further evaluation. In THP-1-derived macrophages, talazoparib reduced oxLDL-induced intracellular neutral-lipid accumulation at a sub-cytotoxic concentration. In a complementary DiI-oxLDL assay, all three compounds reduced cell-associated DiI-oxLDL fluorescence relative to vehicle control. These findings provide preliminary computational and cellular support for further investigation of the selected compounds. However, direct binding to or inhibition of VAV2 has not been demonstrated and requires biochemical, genetic, pharmacological, and in vivo validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-vavFoam CellsAtherosclerosisDrug RepositioningHumansMolecular Docking SimulationMolecular Dynamics SimulationLipoproteins, LDLStructure-Activity RelationshipTHP-1 Cells

Stichwörter der Autor:innen

AtherosclerosisCoronary artery disease (CAD)Drug repurposingFoam cellsMolecular dockingVAV2

Substanzen

Proto-Oncogene Proteins c-vavLipoproteins, LDLoxidized low density lipoproteinVAV2 protein, human

Autor:innen und Institutionen

  • Dr. B.R. Ambedkar Center for Biomedical Research, University of Delhi, Delhi, 110007, India.
  • Dr. B.R. Ambedkar Center for Biomedical Research, University of Delhi, Delhi, 110007, India. kamna605@gmail.com.

ORCID-Profile: Kamna Srivastava

Zitieren

APA

Bansal, P., & Srivastava, K. (2026). Structure-based drug repurposing and in vitro evaluation of VAV2-associated candidates for suppression of macrophage foam-cell formation in atherosclerosis. Molecular Diversity, 30(6), 11153-11176. https://doi.org/10.1007/s11030-026-11713-0

Vancouver

Bansal P, Srivastava K. Structure-based drug repurposing and in vitro evaluation of VAV2-associated candidates for suppression of macrophage foam-cell formation in atherosclerosis. Molecular Diversity. 2026;30(6):11153-11176. doi:10.1007/s11030-026-11713-0

BibTeX
@article{Bansal2026,
  author = {Bansal, Prerna and Srivastava, Kamna},
  title = {Structure-based drug repurposing and in vitro evaluation of VAV2-associated candidates for suppression of macrophage foam-cell formation in atherosclerosis},
  journal = {Molecular Diversity},
  year = {2026},
  volume = {30},
  number = {6},
  pages = {11153--11176},
  doi = {10.1007/s11030-026-11713-0}
}
Kostenlos starten →